Pharma Journalist -

The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical…
Read More...

SMi Reports: The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics RNA therapeutics is a rapidly expanding industry with…
Read More...

Taiho Pharmaceutical Co., Ltd and Lung Therapeutics, Inc. announced an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently…
Read More...

Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, and OneThree Biotech, a…
Read More...

Pfizer and BioNTech SE announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine…
Read More...

Brazil's National Health Surveillance Agency (Anvisa) authorizes resumption of the phase III clinical trial of CoronaVac™, the Inactivated COVID-19 Vaccine, which is sponsored by our…
Read More...

It’s an exciting time for gene therapy! The FDA expects 40-60 gene therapy products to be approved in the US alone before 2030. So, the medical affairs role has never been more vital in…
Read More...

Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the…
Read More...

Medigen Vaccine Biologics Corporation, a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held…
Read More...

Xencor, MorphoSys AG and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with…
Read More...